Advertisement

Inhibition of IκB Kinase 2 Attenuated the Proliferation and Induced Apoptosis of Gastric Cancer

  • Hui Cao
  • Sihong Jiang
  • Ruitao Yuan
  • Wei Zhang
  • Yun Liu
  • Chen ShaoEmail author
  • Shihe ShaoEmail author
Original Article
  • 31 Downloads

Abstract

Background

IκB kinase 2 (IKK2) is the primary catalytic subunit of the IKK complex. Activation of IKK phosphorylates the inhibitors of NF-κB (IκB), triggering the translocation of NF-κB.

Aims

Although IKK2 has been investigated in the inflammation-cancer transformation of gastric epithelium, its role in gastric cancer (GC) cells remained unexplored.

Methods

The IKK2 distribution and expression were measured by immunochemistry staining in clinical specimens. The proliferation, apoptosis, and migration of GC cells were analyzed after IKK2 expression intervention. Using Erk and β-catenin inhibitors, we investigated the relationship between IKK2 and Erk and β-catenin pathways. In the GC-burdened mice, we confirmed the effects of IKK2 inhibition on tumor growth.

Results

Here, we found that IKK2 expression in the GC area was even higher than adjacent inflammatory area, and the GC patients with high expression of IKK2 showed worse overall and disease-free survival. Introduction of IKK2 inhibitor SC-514 inhibited the cell proliferation and induced apoptosis of SGC-7901 cells, in turn overexpression of IKK2 in MGC-823 cells showed the reverse effects. The proliferative activity of IKK2 on GC cells was dependent on the activation of β-catenin and Erk pathways. Additionally, IKK2 alteration affected the migration of GC cells. In vivo, IKK2 inhibition mitigated the tumor growth. Decreased expression of PCNA as well as an increase in cleaved caspase 3 and p53 were observed.

Conclusion

Our results indicate that IKK2 promotes the GC cell proliferation and inhibits their apoptosis, suggesting it may be a potential target for GC therapy.

Keywords

IκB kinase 2 Gastric cancer Proliferation Apoptosis β-Catenin 

Notes

Acknowledgments

The authors acknowledge the National Natural Science Foundation of China (Grant No. 81772157), Natural Science Foundation of Jiangsu Province, China (Grant No. BK20161345), Key Science Research Project in Colleges and Universities of Jiangsu Province, China (Grant No. 17KJA320001).

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Supplementary material

10620_2018_5414_MOESM1_ESM.pdf (57 kb)
Supplementary material 1 (PDF 56 kb)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  2. 2.
    Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–2664.CrossRefGoogle Scholar
  3. 3.
    Sui Y, Park SH, Xu J, et al. IKKbeta links vascular inflammation to obesity and atherosclerosis. J Exp Med. 2014;211:869–886.CrossRefGoogle Scholar
  4. 4.
    Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57.CrossRefGoogle Scholar
  5. 5.
    Liu B, Sun L, Liu Q, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27:370–381.CrossRefGoogle Scholar
  6. 6.
    Yan J, Xiang J, Lin Y, et al. Inactivation of BAD by IKK inhibits TNFalpha-induced apoptosis independently of NF-kappaB activation. Cell. 2013;152:304–315.CrossRefGoogle Scholar
  7. 7.
    Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–296.CrossRefGoogle Scholar
  8. 8.
    Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121:977–990.CrossRefGoogle Scholar
  9. 9.
    Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–113.CrossRefGoogle Scholar
  10. 10.
    Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14:408–419.CrossRefGoogle Scholar
  11. 11.
    Pannicke U, Baumann B, Fuchs S, et al. Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med. 2013;369:2504–2514.CrossRefGoogle Scholar
  12. 12.
    Xia Y, Yeddula N, Leblanc M, et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol. 2015;17:532.CrossRefGoogle Scholar
  13. 13.
    Szasz AM, Lanczky A, Nagy A, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7:49322–49333.CrossRefGoogle Scholar
  14. 14.
    Campisi J, Gray HE, Pardee AB, Dean M, Sonenshein GE. Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell. 1984;36:241–247.CrossRefGoogle Scholar
  15. 15.
    Prelich G, Tan CK, Kostura M, et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature. 1987;326:517–520.CrossRefGoogle Scholar
  16. 16.
    Sui Y, Liu Z, Park SH, et al. IKKbeta is a beta-catenin kinase that regulates mesenchymal stem cell differentiation. JCI Insight. 2018;3:96660.CrossRefGoogle Scholar
  17. 17.
    Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci U S A. 2009;106:2629–2634.CrossRefGoogle Scholar
  18. 18.
    Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–436.CrossRefGoogle Scholar
  19. 19.
    Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci. 2007;98:268–274.CrossRefGoogle Scholar
  20. 20.
    Patel M, Horgan PG, McMillan DC, Edwards J. NF-kappaB pathways in the development and progression of colorectal cancer. Transl Res J Lab Clin Med. 2018;197:43–56.CrossRefGoogle Scholar
  21. 21.
    Cahill KE, Morshed RA, Yamini B. Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy. Neuro-oncology. 2016;18:329–339.CrossRefGoogle Scholar
  22. 22.
    Sigal M, Logan CY, Kapalczynska M, et al. Stromal R-spondin orchestrates gastric epithelial stem cells and gland homeostasis. Nature. 2017;548:451–455.CrossRefGoogle Scholar
  23. 23.
    Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012;12:121–132.CrossRefGoogle Scholar
  24. 24.
    Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: ‘one size does not fit all’. Oncogene. 2011;30:1615–1630.CrossRefGoogle Scholar
  25. 25.
    Tse AK, Chen YJ, Fu XQ, et al. Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKbeta inhibition. Redox Biol. 2017;11:562–576.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Digestive Disease Center, Shanghai East HospitalTongji UniversityShanghaiChina
  2. 2.School of MedicineJiangsu UniversityZhenjiangChina
  3. 3.Department of CardiologyAffiliated Hospital of Jiangsu UniversityZhenjiangChina

Personalised recommendations